65 related articles for article (PubMed ID: 12869651)
1. Msh2 deficiency attenuates but does not abolish thiopurine hematopoietic toxicity in msh2-/- mice.
Krynetskaia NF; Brenner TL; Krynetski EY; Du W; Panetta JC; Ching-Hon P; Evans WE
Mol Pharmacol; 2003 Aug; 64(2):456-65. PubMed ID: 12869651
[TBL] [Abstract][Full Text] [Related]
2. Selective radiosensitization of drug-resistant MutS homologue-2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: Msh2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell cycle effects of the dThd analogues and 6-thioguanine.
Berry SE; Davis TW; Schupp JE; Hwang HS; de Wind N; Kinsella TJ
Cancer Res; 2000 Oct; 60(20):5773-80. PubMed ID: 11059773
[TBL] [Abstract][Full Text] [Related]
3. Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells.
Dervieux T; Blanco JG; Krynetski EY; Vanin EF; Roussel MF; Relling MV
Cancer Res; 2001 Aug; 61(15):5810-6. PubMed ID: 11479220
[TBL] [Abstract][Full Text] [Related]
4. Msh-2 suppresses in vivo mutation in a gene dose and lesion dependent manner.
Sansom OJ; Toft NJ; Winton DJ; Clarke AR
Oncogene; 2001 Jun; 20(27):3580-4. PubMed ID: 11429706
[TBL] [Abstract][Full Text] [Related]
5. Cell lineage-specific effects associated with multiple deficiencies of tumor susceptibility genes in Msh2(-/-)Rb(+/-) mice.
Nikitin AY; Liu CY; Flesken-Nikitin A; Chen CF; Chen PL; Lee WH
Cancer Res; 2002 Sep; 62(18):5134-8. PubMed ID: 12234974
[TBL] [Abstract][Full Text] [Related]
6. Single cell tracking reveals that Msh2 is a key component of an early-acting DNA damage-activated G2 checkpoint.
Marquez N; Chappell SC; Sansom OJ; Clarke AR; Court J; Errington RJ; Smith PJ
Oncogene; 2003 Oct; 22(48):7642-8. PubMed ID: 14576827
[TBL] [Abstract][Full Text] [Related]
7. Role of MUTYH and MSH2 in the control of oxidative DNA damage, genetic instability, and tumorigenesis.
Russo MT; De Luca G; Casorelli I; Degan P; Molatore S; Barone F; Mazzei F; Pannellini T; Musiani P; Bignami M
Cancer Res; 2009 May; 69(10):4372-9. PubMed ID: 19435918
[TBL] [Abstract][Full Text] [Related]
8. Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia.
Dervieux T; Hancock ML; Pui CH; Rivera GK; Sandlund JT; Ribeiro RC; Boyett J; Evans WE; Relling MV
Clin Pharmacol Ther; 2003 Jun; 73(6):506-16. PubMed ID: 12811360
[TBL] [Abstract][Full Text] [Related]
9. The effect of Msh2 knockdown on methylating agent induced toxicity in DNA glycosylase deficient cells.
Cooley N; Elder RH; Povey AC
Toxicology; 2010 Jan; 268(1-2):111-7. PubMed ID: 20025921
[TBL] [Abstract][Full Text] [Related]
10. (CAG)(n)-hairpin DNA binds to Msh2-Msh3 and changes properties of mismatch recognition.
Owen BA; Yang Z; Lai M; Gajec M; Badger JD; Hayes JJ; Edelmann W; Kucherlapati R; Wilson TM; McMurray CT
Nat Struct Mol Biol; 2005 Aug; 12(8):663-70. PubMed ID: 16025128
[TBL] [Abstract][Full Text] [Related]
11. The ability to engage enterocyte apoptosis does not predict long-term crypt survival in p53 and Msh2 deficient mice.
Sansom OJ; Clarke AR
Oncogene; 2002 Aug; 21(38):5934-9. PubMed ID: 12185594
[TBL] [Abstract][Full Text] [Related]
12. A lack of DNA mismatch repair on an athymic murine background predisposes to hematologic malignancy.
Campbell MR; Nation PN; Andrew SE
Cancer Res; 2005 Apr; 65(7):2626-35. PubMed ID: 15805259
[TBL] [Abstract][Full Text] [Related]
13. Msh2 deficiency leads to chromosomal abnormalities, centrosome amplification, and telomere capping defect.
Campbell MR; Wang Y; Andrew SE; Liu Y
Oncogene; 2006 Apr; 25(17):2531-6. PubMed ID: 16331258
[TBL] [Abstract][Full Text] [Related]
14. Spontaneous and mutagen-induced loss of DNA mismatch repair in Msh2-heterozygous mammalian cells.
Borgdorff V; van Hees-Stuivenberg S; Meijers CM; de Wind N
Mutat Res; 2005 Jul; 574(1-2):50-7. PubMed ID: 15914206
[TBL] [Abstract][Full Text] [Related]
15. Functional analysis of HNPCC-related missense mutations in MSH2.
Lützen A; de Wind N; Georgijevic D; Nielsen FC; Rasmussen LJ
Mutat Res; 2008 Oct; 645(1-2):44-55. PubMed ID: 18822302
[TBL] [Abstract][Full Text] [Related]
16. DNA mismatch repair proteins promote apoptosis and suppress tumorigenesis in response to UVB irradiation: an in vivo study.
Young LC; Thulien KJ; Campbell MR; Tron VA; Andrew SE
Carcinogenesis; 2004 Oct; 25(10):1821-7. PubMed ID: 15166087
[TBL] [Abstract][Full Text] [Related]
17. Conditional expression of mutated K-ras accelerates intestinal tumorigenesis in Msh2-deficient mice.
Luo F; Brooks DG; Ye H; Hamoudi R; Poulogiannis G; Patek CE; Winton DJ; Arends MJ
Oncogene; 2007 Jun; 26(30):4415-27. PubMed ID: 17297472
[TBL] [Abstract][Full Text] [Related]
18. Activation of nuclear receptor Nur77 by 6-mercaptopurine protects against neointima formation.
Pires NM; Pols TW; de Vries MR; van Tiel CM; Bonta PI; Vos M; Arkenbout EK; Pannekoek H; Jukema JW; Quax PH; de Vries CJ
Circulation; 2007 Jan; 115(4):493-500. PubMed ID: 17242285
[TBL] [Abstract][Full Text] [Related]
19. Involvement of the concentrative nucleoside transporter 3 and equilibrative nucleoside transporter 2 in the resistance of T-lymphoblastic cell lines to thiopurines.
Fotoohi AK; Lindqvist M; Peterson C; Albertioni F
Biochem Biophys Res Commun; 2006 Apr; 343(1):208-15. PubMed ID: 16530731
[TBL] [Abstract][Full Text] [Related]
20. The effect of thiopurine drugs on DNA methylation in relation to TPMT expression.
Hogarth LA; Redfern CP; Teodoridis JM; Hall AG; Anderson H; Case MC; Coulthard SA
Biochem Pharmacol; 2008 Oct; 76(8):1024-35. PubMed ID: 18708030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
